ATP and adenosine inhibit transmitter release at the frog neuromuscular junction through distinct presynaptic receptors
- 1 June 1998
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 124 (4) , 839-844
- https://doi.org/10.1038/sj.bjp.0701881
Abstract
1. The effects of exogenous ATP or adenosine on end-plate currents (e.p.cs; evoked by simultaneous action of a few hundred quanta of ACh) or on miniature e.p.cs (m.e.p.cs) were studied under voltage clamp conditions on frog sartorius muscle fibres. 2. ATP or adenosine (100 microM(-1) mM) reduced the e.p.c. amplitude but did not affect m.e.p.c. amplitude, decay time constant and voltage-dependence of m.e.p.c., suggesting that e.p.c. depression induced by these purines had presynaptic origin only. 3. The action of ATP, unlike that of adenosine, was prevented by the P2-purinoceptor antagonist suramin (100 microM). The stable ATP analogue alpha,beta-methylene ATP (100 microM), known to be desensitizing agent on P2X receptors, also abolished the depressant effect of ATP while sparing the action of adenosine. Concanavalin A, an inhibitor of ecto-5'-nucleotidase, did not affect the presynaptic action of exogenously applied ATP. 4. The presynaptic action of adenosine was prevented by theophylline (1 mM), a blocker of adenosine receptors, while the effect of ATP was not changed under these conditions. The selective blocker of A1 adenosine receptors, 8-cyclopentyl-1,3,dipropylxanthine (DPCPX; 0.1 microM), abolished the presynaptic action of adenosine but did not prevent the depressant effect of ATP. 5. The effects of ATP and adenosine (at nearly saturating concentration) were additive suggesting that these purines activated not only distinct receptors but also different intracellular signalling mechanisms. 6. In contrast to the hypothesis that at the neuromuscular junction ATP reduces transmitter release via enzymatic degradation to presynaptically active adenosine, our data suggest that ATP (through its own presynaptic receptors) directly inhibits ACh release. Thus, ATP and adenosine might be almost equipotent as endogenous prejunctional neuromodulators at the neuromuscular junction.Keywords
This publication has 27 references indexed in Scilit:
- Is there a basis for distinguishing two types of P2-purinoceptor?Published by Elsevier ,2002
- An ATP-activated, ligand-gated ion channel on a cholinergic presynaptic nerve terminal.Proceedings of the National Academy of Sciences, 1996
- Chapter 23 Purinergic regulation of acetylcholine releasePublished by Elsevier ,1996
- A P2X purinoceptor expressed by a subset of sensory neuronsNature, 1995
- Acetylcholinesterase density and turnover number at frog neuromuscular junctions, with modeling of their role in synaptic functionNeuron, 1994
- Pharmacological activity of adenine dinucleotides in the periphery: Possible receptor classes and transmitter functionGeneral Pharmacology: The Vascular System, 1990
- Short-Term Synaptic PlasticityAnnual Review of Neuroscience, 1989
- Suramin: a reversible P2‐purinoceptor antagonist in the mouse vas deferensBritish Journal of Pharmacology, 1988
- 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX) ? a selective high affinity antagonist radioligand for A1 adenosine receptorsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1987
- THE EFFECTS OF ADENOSINE TRIPHOSPHATE AND ADENOSINE DIPHOSPHATE ON TRANSMISSION AT THE RAT AND FROG NEUROMUSCULAR JUNCTIONSBritish Journal of Pharmacology, 1975